PRF自体富纤维蛋白再生治疗
皮肤美容
≈ ¥2000-5000
(≈ $280-700)
大约2-4小时（含采血、离心制备及局部注射）
免责声明：本站为医疗服务机构，页面信息部分由AI协助制作。健康相关信息不构成医疗建议。如有任何疑问，请咨询医疗专业人士。详情见免责声明
项目介绍
PRF自体富纤维蛋白再生治疗在一般公立医院参考费用约¥1400-4000，三甲医院参考费用约¥2000-5000，常用于相关诊断评估与就医安排，费用随医院及地区有所差异。
主要用途
PRF autologous regenerative therapy is primarily used in oral and maxillofacial surgery (e.g., socket preservation, sinus lift, ridge augmentation, periodontal defect regeneration), orthopedics (tendon/ligament healing, osteoarthritis intra-articular injection), dermatology (chronic wound healing, alopecia, facial rejuvenation), and ENT (tympanic membrane repair). Its main purposes include accelerating soft and hard tissue healing, modulating inflammation, delivering sustained-release growth factors, enhancing angiogenesis, and serving as a natural scaffold for cell migration—without exogenous additives or animal-derived components.
正常值范围
PRF (Platelet-Rich Fibrin) is not a standardized blood test with quantitative 'normal ranges' like conventional lab assays. It is an autologous biologic preparation derived from centrifuged venous blood; therefore, no universal numerical reference intervals exist for 'PRF levels'. Instead, quality assessment focuses on qualitative and semi-quantitative parameters: platelet concentration (typically 3–8× baseline whole blood), fibrin matrix density (visual/tactile evaluation), leukocyte content (moderate to high, depending on centrifugation protocol), and growth factor release kinetics (e.g., PDGF-BB, TGF-β1, VEGF — measured in research settings only, not clinically routine). Clinical protocols define success by morphological integrity (intact, cohesive clot), color (amber-yellow), elasticity, and absence of hemolysis or serum separation.
偏低可能原因
1. Inadequate venous blood draw volume or improper collection tube (non-additive or EDTA tubes inhibit fibrin polymerization); 2. Suboptimal centrifugation parameters (insufficient g-force, duration, or incorrect brake setting causing clot disruption); 3. Patient-related factors including severe thrombocytopenia (<100 × 10⁹/L), chronic platelet dysfunction (e.g., aspirin/NSAID use within 7–10 days), advanced age (>75 years), uncontrolled diabetes, or systemic inflammation; 4. Anticoagulant therapy (e.g., warfarin, DOACs) interfering with fibrin formation; 5. Hemodilution or acute blood loss prior to collection.
偏高可能原因
1. Excessive centrifugal force or prolonged spin time leading to over-compaction, reduced bioactivity, and diminished growth factor retention; 2. High baseline platelet count (thrombocytosis >450 × 10⁹/L), often associated with reactive or clonal myeloproliferative disorders; 3. Acute inflammatory states (e.g., active infection, recent surgery) increasing circulating leukocytes and cytokines incorporated into PRF; 4. Use of low-speed, single-spin protocols that retain excessive red blood cells (RBCs), falsely elevating total clot mass but compromising purity and clinical efficacy; 5. Operator-dependent variability in tube filling and handling causing inconsistent fibrin network architecture.